Diamyd Medical - Targeting the Underlying Causes of Diabetes

Press Releases

June 18, 2019

June 4, 2019 Denmark

	Dates for financial information and other events
	June 26, 2019 Quarterly Report III Quarterly Report 3 2018/2019
	June 27, 2019 Quarterly Report III presentation CEO Ulf Hannelius presents live at 10.00 CET
	August 28 − August 29, 2019 LSX Nordic Congress Stockholm, Sweden
	October 2, 2019 Year-End Report Year-End Report 2018/2019

We are seeing increased international visibility highlighting the work we are doing.

Ulf Hannelius
President and CEO, Diamyd Medical AB

Read more

Diabetes

10-20% of the more than 400 million living with diabetes suffer from the autoimmune form of the disease, where the immune system destroys the insulin-producing cells. Preserving the insulin producing ability may decrease the risk of complications among patients with autoimmune diabetes by 60-80 percent.
Read more

Products

The antigen-specific immunotherapy Diamyd^® and the regenerative and immunomodulatory therapy Remygen^® are two novel disease-modifying drugs in clinical development phase, aiming to preserve and regenerate the patients’ own insulin production.
Read more

Clinical Trials

The efficacy of intralymphatic administration of Diamyd^® on preserving the insulin producing ability in type 1 diabetes is being confirmed in the Phase IIb trial DIAGNODE-2. The safety and efficacy of Remygen^® on stimulating growth of insulin producing cells in type 1 diabetes is being evaluated for the first time in the Phase I/II trial ReGenerate-1.

Share This Page